HistoSonics Spearheads $2.25B Acquisition by Elite Investor Consortium
Deal News | Aug 07, 2025 | HealthQuest Capital Management
HistoSonics, a pioneering medical device company in non-invasive tumor therapy, has announced a management-led acquisition valued at approximately $2.25 billion. The acquisition is supported by a consortium of well-known private and public investors, including K5 Global and Bezos Expeditions, illustrating significant confidence in HistoSonics' innovative Edison Histotripsy System. This strategic move is set to expedite the global expansion and application of HistoSonics' cutting-edge platform, initially targeting liver tumor treatment but with plans to extend to kidneys, pancreas, and prostate. Continued leadership under CEO Mike Blue, alongside the company’s strategic investor partnerships, positions HistoSonics to evolve histotripsy technologies and widen their clinical reach. With FDA De Novo clearance attained in October 2023, HistoSonics is leading the charge in leveraging focused ultrasound technologies to deliver non-invasive, targeted tumor destruction, currently serving patients across the U.S. while planning numerous further installations. Financial advisory was provided by Citi, with legal advisement by Fox Rothschild.
Sectors
- Healthcare Technology
- Medical Devices
- Private Equity & Investment
Geography
- United States – HistoSonics is a U.S.-based company with key operations in Minneapolis, MN, and Ann Arbor, MI. Their Edison System is being implemented in medical centers across the U.S.
Industry
- Healthcare Technology – HistoSonics operates in the healthcare technology sector, focusing on developing non-invasive methods for tumor treatment using histotripsy.
- Medical Devices – The development of the Edison Histotripsy System places HistoSonics squarely in the medical devices industry.
- Private Equity & Investment – The article discusses a major acquisition involving global investment firms, reflecting significant investment activity in the private equity sector.
Financials
- $2.25 billion – The valuation of HistoSonics in the management-led acquisition deal by a consortium of investors.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| HistoSonics | Target Company | Companies | A privately held medical device company developing the Edison Histotripsy System. |
| HealthQuest Capital | Investor | Companies | A private equity firm involved in the acquisition of HistoSonics. |
| K5 Global | Investor | Companies | A top-tier investment firm participating in the acquisition of HistoSonics. |
| Bezos Expeditions | Investor | Companies | An investor involved in HistoSonics' acquisition, representing Jeff Bezos' personal investment company. |
| Citi | Financial Advisor to HistoSonics | Companies | Provided financial advisory services in the acquisition. |
| Fox Rothschild | Legal Advisor to HistoSonics | Companies | Provided legal advisory services to HistoSonics in the deal. |
| Morgan Stanley & Co. LLC | Financial Advisor to the Investment Syndicate | Companies | Provided financial advisory services to the investment syndicate involved in the acquisition of HistoSonics. |
| Cooley | Legal Advisor to the Investment Syndicate | Companies | Provided legal advisory services to the investment syndicate involved in the acquisition of HistoSonics. |
| Orrick | Legal Assistant to Cooley | Companies | Assisted Cooley and provided additional legal advisory services in the acquisition. |
| Wilson Sonsini Goodrich & Rosati | Legal Advisor to HistoSonics' existing major shareholders | Companies | Provided legal advisory services to existing major shareholders of HistoSonics. |